drugset
drugset / Trial / NCT02454075

YF476 and Type II Gastric Carcinoids

NCT02454075 ↗

Phase 2 Terminated 3 enrolled Trio Medicines Ltd. National Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.

Timeline

Start
2011-04-11
Primary completion
2012-06-22
Completion
2012-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject netazepide Protein / enzyme biologic 100 mg —
Subject netazepide Protein / enzyme biologic 150 mg —
Subject netazepide Protein / enzyme biologic 200 mg —

Indications

Zollinger-Ellison syndrome